Biohaven’s previously rejected rare disease drug to get fresh FDA review
Biohaven's Vyglxia, a drug for spinocerebellar ataxia, will undergo a fresh FDA review after a previous rejection. The FDA will convene an expert panel and issue a decision in Q1 2024. Biohaven claims to have submitted new supportive analyses. The announcement caused a 25% rise in shares and optimistic analyst notes, with some predicting over $1 billion in annual sales if approved.
How this was made
The 30-second read
Why it matters
The FDA advisory committee meeting increases the likelihood of approval, driving a strong positive market reaction.
Market read
First report of FDA panel acceptance; significant upside potential for BHVN and rare‑disease biotech sector.
What to watch
The drug still faces European regulatory hurdles and may require additional data to secure approval.
Background
Biohaven, a developer of rare‑disease therapies, is seeking FDA approval for Vyglxia, a treatment for spinocerebellar ataxia.
Ticker impact
Biohaven received FDA acceptance for a second review of Vyglxia, prompting a ~25% share surge.
upward pressure as investors bet on potential FDA approval
The FDA advisory panel meeting substantially raises approval odds, and the stock already jumped 25% on the news.
Market effects
Potential boost for rare‑disease biotech sector as FDA shows more flexibility.
U.S. biotech stocks may see modest gains on the news.
Limited to investors focused on U.S. biotech and rare‑disease therapeutics.
Counterpoint
If the FDA panel raises concerns, the stock could reverse the rally quickly.
Key entities
- companyBiohaven Pharmaceutical
U.S. biotech focused on rare‑disease drugs, ticker BHVN.
- drugVyglxia
Investigational therapy for spinocerebellar ataxia.
